New research reveals that individuals who discontinue popular weight-loss injections like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who stop traditional lifestyle programs.
Research printed in a leading medical journal demonstrates that while obese people often shed about a fifth of their total mass while on the medication, the weight comes back at an estimated rate of 0.8 kg per month once they quit.
"People purchasing these treatments must be informed of the danger of fast weight regain when the medication is stopped," cautioned lead investigator Dr. Susan Jebb.
That rate of recovery implies a reversion to starting weight within about a year and a half.
Weighing Treatments
The study, which examined 37 of studies involving thousands of participants, contrasted the outcomes of the injectable medications with older methods.
The team point out that individuals who lose weight through lifestyle changes alone usually experience a more gradual weight regain—perhaps 100 grams monthly—post-intervention.
The Reason for the Quick Regain
Nutrition scientists suggest the way of the injections explains the amplified regain.
GLP-1 drugs copy a body's own chemical called GLP-1, which controls hunger.
"Artificially providing the hormone concentrations far above than normal may cause the body to produce less of its own natural GLP-1, and could diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this GLP-1 'fix' leads to appetite is unsuppressed, making binge eating much more probable."
A Chronic Issue?
Medical guidelines recommend the jabs for people with weight-linked health risks, alongside recommended lifestyle changes.
Many experts contend that, due to the high risk of relapse, the treatment might need to be life-long.
This perspective is reinforced by drug manufacturers, who state that the findings "highlight the persistent nature of obesity," similar to managing diseases like diabetes.
Patient Accounts
Users who have discontinued the medication report a powerful return of appetite.
"It felt as if something that goes on and you're instantly extremely hungry," described a patient.
The struggle is worsened if patients have not adopted permanent dietary or behavioural changes during therapy.
Significant Interest
Figures show that a significant number of adults in the UK have tried weight-loss jabs in the past year, with desire being substantial.
- Adoption is more common among females than males.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion obtain the drugs through private healthcare rather than public health services.
Finally, clinicians stress that while these medications are effective tools for shedding pounds, they are not a magic solution and long-term success likely depends on ongoing lifestyle support.
